Anti-nuclear autoantibodies in Graves' disease and Graves' orbitopathy.

Anti-nuclear autoantibodies Graves’ disease Graves’ ophthalmopathy Graves’ orbitopathy Non-organ-specific autoantibodies Thyroid eye disease

Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 22 03 2022
accepted: 18 08 2022
pubmed: 28 8 2022
medline: 25 1 2023
entrez: 27 8 2022
Statut: ppublish

Résumé

A relationship between thyroid and non-organ-specific autoimmunity could be relevant for Graves' orbitopathy (GO), which affects connective tissue. We investigated the association between GO and anti-nuclear antibodies (ANAs). Retrospective investigation was conducted in 265 patients with Graves' disease (GD), 158 with and 107 without GO. Primary outcome was: prevalence of ANAs in GO vs no-GO. Secondary outcomes were: (1) relationship between ANAs and GO features; (2) prevalence of ANAs in GD compared with non-autoimmune hyperthyroidism [(78 patients with toxic nodular goiter (TNG)]; (3) distribution of ANA patterns. ANAs were detected in 212 (80%) GD patients, but prevalence did not differ between GO (79.7%) and no-GO (80.3%). Higher ANA titers (1:160) were more common in GO (51.5 vs 38.3%), but only nearly significantly (OR 0.5; 95% CI: 0.3-1; P = 0.059). Proptosis was lower in ANA-positive patients (mean difference: - 1.4 mm; 95% CI from - 2.5 to - 0.3; P = 0.011), in whom nearly significantly lower CAS (Mann-Whitney U: 1.5; P = 0.077) and eyelid aperture (mean difference: - 0.9 mm; 95% CI from - 2 to 0; P = 0.062) were observed. Prevalence of ANAs in GD was lower than in TNG (80 vs 91%; OR 0.3; 95% CI: 0.1-0.9; P = 0.028), but nuclear speckled pattern was more frequent (OR 22.9; 95% CI 1.3-381.3; P = 0.028). Although ANAs are not more frequent in GO, they seem to exert a protective role on its severity and on development of GD. A switch of T cell population in ANA-positive patients, resulting in a different phenotype, may be responsible. Further studies are needed to investigate the mechanisms.

Identifiants

pubmed: 36030301
doi: 10.1007/s40618-022-01906-3
pii: 10.1007/s40618-022-01906-3
pmc: PMC9859920
doi:

Substances chimiques

Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

337-344

Subventions

Organisme : University of Pisa
ID : 539901

Informations de copyright

© 2022. The Author(s).

Références

Autoimmun Rev. 2016 Feb;15(2):162-6
pubmed: 26524640
Ann Rheum Dis. 2019 Jul;78(7):879-889
pubmed: 30862649
Indian J Endocrinol Metab. 2012 Jul;16(4):569-74
pubmed: 22837918
J Endocrinol Invest. 2016 Apr;39(4):357-73
pubmed: 26392367
Med Princ Pract. 2018;27(4):332-336
pubmed: 29864750
Nat Rev Rheumatol. 2020 Dec;16(12):715-726
pubmed: 33154583
J Endocrinol Invest. 2020 Dec;43(12):1759-1768
pubmed: 32583374
J Endocrinol Invest. 2022 Mar;45(3):563-572
pubmed: 34671950
Best Pract Res Clin Endocrinol Metab. 2005 Mar;19(1):17-32
pubmed: 15826920
Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101462
pubmed: 31848055
J Endocrinol Invest. 2022 Feb;45(2):235-259
pubmed: 34417736
J Endocrinol Invest. 2021 Dec;44(12):2575-2579
pubmed: 33844165
Int J Mol Sci. 2020 Feb 18;21(4):
pubmed: 32085664
Clin Ter. 1992 Sep;141(9 Pt 2):49-54
pubmed: 1468198
Ann Rheum Dis. 2014 Jan;73(1):17-23
pubmed: 24126457
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67
pubmed: 34297684
Pol Arch Med Wewn. 2012;122 Suppl 1:55-9
pubmed: 23222800
Medicine (Baltimore). 2016 Sep;95(38):e4336
pubmed: 27661011
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2176-e2190
pubmed: 33484567
J Immunol Res. 2018 Dec 17;2018:6895146
pubmed: 30911555
Lab Med. 2018 Jul 5;49(3):e62-e73
pubmed: 29868860
J Endocrinol Invest. 2022 Jan;45(1):189-197
pubmed: 34324163
J Endocrinol Invest. 2021 Apr;44(4):703-712
pubmed: 32749654
J Endocrinol Invest. 2021 Mar;44(3):581-585
pubmed: 32648002
J Immunol Res. 2014;2014:150239
pubmed: 24741574
Lupus. 2004;13(6):450-4
pubmed: 15303572

Auteurs

G Lanzolla (G)

Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

L Puccinelli (L)

Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

M Giudetti (M)

Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

S Comi (S)

Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

F Menconi (F)

Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

M N Maglionico (MN)

Department of Surgical, Medical and Molecular Pathology, Ophthalmology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

C Posarelli (C)

Department of Surgical, Medical and Molecular Pathology, Ophthalmology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

M Figus (M)

Department of Surgical, Medical and Molecular Pathology, Ophthalmology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

C Marcocci (C)

Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

M Marinò (M)

Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy. michele.marino@med.unipi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH